T-cell receptor recognizing Influenza A virus H3N2 hemagglutinin-derived peptides presented by Major Histocompatibility Complex (TCR-H3N2-HA)

The T-cell receptor (TCR) recognizing H3N2 hemagglutinin-derived peptides presented by the Major Histocompatibility Complex (MHC) is a pivotal mediator of the adaptive immune response against Influenza A virus. These receptors are expressed on the surface of T lymphocytes and are specialized to identify specific peptide fragments of the hemagglutinin (HA) protein, such as the well-characterized HA 306-318 epitope, when displayed by MHC molecules like HLA-DR4 (PubMed: 12808450). Binding of the TCR to the peptide-MHC complex initiates a signaling cascade that results in T-cell proliferation and the release of effector molecules, including interferon-gamma and granzymes, which are essential for controlling viral replication (PubMed: 25135944). In clinical practice, these TCRs are the primary targets of seasonal influenza vaccines, which aim to prime the immune system to recognize these viral signatures upon natural exposure (NIH: NIAID). Furthermore, research into TCR-T cell therapies explores the use of engineered T cells expressing these specific receptors to provide protection against severe H3N2 infections in immunocompromised patients. However, the high rate of antigenic drift in the H3N2 hemagglutinin protein poses a significant challenge, as mutations can alter the peptide sequence and prevent TCR recognition, leading to reduced vaccine efficacy and viral escape (PubMed: 30209168). Understanding the structural basis of this interaction is vital for developing universal vaccines that target conserved regions of the HA protein.

Other names

H3N2 hemagglutinin-specific T-cell receptorHA-specific TCRInfluenza A virus H3N2 HA-reactive TCRTCR recognizing H3N2 HA peptides

Recognition of viral peptide-MHC complexes leading to T-cell activation and immune-mediated clearance of infected cells.